Prophylactic Ivermectin in COVID-19 Contacts

COVID Clinical Trial

Official title:

Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04422561
• Other study ID #: ZU-IRB#6150/31-5-2020
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: May 31, 2020
• Est. completion date: July 27, 2020

Study information

• Verified date: August 2020
• Source: Zagazig University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms & diagnosis of COVID -19

Recruitment information / eligibility

• Status: Completed
• Enrollment: 340
• Est. completion date: July 27, 2020
• Est. primary completion date: July 14, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 16 Years to 70 Years

Eligibility

Inclusion Criteria:

family contact of confirmed COVID-19 case

Exclusion Criteria:

• refuse to participate and receive the drug pregnancy or lactation known hypersensitivity to ivermectin

Related Conditions & MeSH terms

• COVID

Intervention

Drug:
• Ivermectin Tablets
two doses 72 hours apart

Locations

Country	Name	City	State
Egypt	Zagazig University	Zagazig	Sharkia

Sponsors (1)

Lead Sponsor	Collaborator
Zagazig University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Development of Symptoms ( Fever ,Cough, Sore Throat, Myalgia,Diarrhea, Shortness of Breath)	history taking and clinical examination	within 14 days after enrollement
Secondary	Development of COVID	by swab	within 14 days after enrollement